Amniotics – Presentation of Q3 Quarterly Report
On friday the 12th of November at 11:30 you have the opportunity to meet and ask questions to CEO Kåre Engkilde, when he presents the Q3 quarterly Results from Amniotics AB.
Amniotics AB is a biopharma company focusing on mesenchymal stem cells (MSC) from amniotic fluid. The company was born out of the discovery of a novel source of stem cells in full-term amniotic fluid.
Amniotics also has an, by Läkemedelsverket (MPA in Sweden), approved Good Manufacturing Practice (GMP) manufacturing facility to produce Advanced therapy medicinal products (ATMPs). With the GMP facility operational since 2020, Amniotics is now moving into clinical development with the leading drug candidate, PulmoStem™ and is looking to establish strategic partnerships with researchers and companies that are interested in developing stem-cell-based therapies targeting diseases with high unmet needs.
The Company has it’s headquarter in Lund – Sweden and listed on Nasdaq First North Growth Market.